Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection.

Citation data:

International journal of STD & AIDS, ISSN: 1758-1052, Vol: 27, Issue: 6, Page: 447-52

Publication Year:
2016
Usage 173
Abstract Views 132
Link-outs 41
Captures 35
Exports-Saves 32
Readers 3
Citations 4
Citation Indexes 4
Repository URL:
https://touroscholar.touro.edu/tcopny_pubs/54; https://touroscholar.touro.edu/tcopny_pubs/101
PMID:
25957325
DOI:
10.1177/0956462415585448
Author(s):
Park, Tae Eun; Mohamed, Abdilahi; Kalabalik, Julie; Sharma, Roopali
Publisher(s):
SAGE Publications; Touro Scholar
Tags:
Medicine; dolutegravir; elvitegravir; human immunodeficiency virus; integrase strand transfer inhibitor; raltegravir; aspirin; HIV; statins; retrospective cross-sectional study; Pharmacy and Pharmaceutical Sciences; Virus Diseases; Chemicals and Drugs
article description
This retrospective, cross-sectional study evaluated whether HIV-infected patients received aspirin and statins for the primary prevention of myocardial infarction and stroke. Among the 258 patients included, 50.4% (n = 130/258) of the patients had a high risk of myocardial infarction and 14% (n = 36/258) of stroke. Overall, 43.1% (n = 56/130) and 50% (n = 18/36) of the patients were prescribed aspirin for the primary prevention of myocardial infarction and stroke, respectively. Among the patients who required statin therapy, 42.5% (n = 34/80) and 37.1% (n = 13/35) of patients received it for the primary prevention of myocardial infarction and stroke, respectively. The patients who had hypertension (odds ratio 3.8, 95% confidence interval 1.5-10.9) and diabetes mellitus (odds ratio 5.6, 95% confidence interval 2.6-12.4) were more likely to receive aspirin. Interventions are needed to improve provider awareness of the use of aspirin and statins in the primary prevention of myocardial infarction and stroke in HIV-infected patients.